title: Role of CYP2A13 in the bioactivation and lung tumorigenicity of the tobacco-specific lung procarcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone: in vivo studies using a CYP2A13-humanized mouse model.
abstract: The tobacco-specific nitrosamine 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK), which is abundant in tobacco smoke, is a potent lung procarcinogen. The present study was aimed to prove that transgenic expression of human cytochrome P450 2A13 (CYP2A13), known to be selectively expressed in the respiratory tract and be the most efficient enzyme for NNK bioactivation in vitro, will enhance NNK bioactivation and NNK-induced tumorigenesis in the mouse lung. Kinetic parameters of NNK bioactivation in vitro and incidence of NNK-induced lung tumors in vivo were determined for wild-type, Cyp2a5-null and CYP2A13-humanized (CYP2A13-transgenic/Cyp2a5-null) mice. As expected, in both liver and lung microsomes, the loss of CYP2A5 resulted in significant increases in Michaelis constant (K m) values for the formation of 4-oxo-4-(3-pyridyl)-butanal, representing the reactive intermediate that can lead to the formation of O(6)-methylguanine (O(6)-mG) DNA adducts; however, the gain of CYP2A13 at a fraction of the level of mouse lung CYP2A5 led to recovery of the activity in the lung, but not in the liver. The levels of O(6)-mG, the DNA adduct highly correlated with lung tumorigenesis, were significantly higher in the lungs of CYP2A13-humanized mice than in Cyp2a5-null mice. Moreover, incidences of lung tumorigenesis were significantly greater in CYP2A13-humanized mice than in Cyp2a5-null mice, and the magnitude of the differences in incidence was greater at low (30mg/kg) than at high (200mg/kg) NNK doses. These results indicate that CYP2A13 is a low K m enzyme in catalyzing NNK bioactivation in vivo and support the notion that genetic polymorphisms of CYP2A13 can influence the risks of tobacco-induced lung tumorigenesis in humans.
authors.affiliation: Wadsworth Center, New York State Department of Health, and School of Public Health, State University of New York at Albany, Empire State Plaza, Box 509, Albany, NY 12201-0509, USA.
authors.forename: Vandana
authors.initials: V
authors.lastname: Megaraj
authors.forename: Xin
authors.initials: X
authors.lastname: Zhou
authors.forename: Fang
authors.initials: F
authors.lastname: Xie
authors.forename: Zhihua
authors.initials: Z
authors.lastname: Liu
authors.forename: Weizhu
authors.initials: W
authors.lastname: Yang
authors.forename: Xinxin
authors.initials: X
authors.lastname: Ding
mesh_terms: D000818:Animals; D001189:Aryl Hydrocarbon Hydroxylases / Q000235:genetics / Q000378:metabolism*; D002273:Carcinogens / Q000493:pharmacokinetics* / Q000633:toxicity; D065637:Cytochrome P-450 CYP2A6; D000072467:Cytochrome P450 Family 2; D018736:DNA Adducts / Q000378:metabolism; D006147:Guanine / Q000031:analogs & derivatives / Q000378:metabolism; D006801:Humans; D008175:Lung Neoplasms / Q000139:chemically induced* / Q000378:metabolism*; D008822:Mice, Transgenic; D008861:Microsomes / Q000187:drug effects / Q000378:metabolism; D009602:Nitrosamines / Q000097:blood / Q000493:pharmacokinetics* / Q000633:toxicity; D011725:Pyridines / Q000493:pharmacokinetics
chemical_list: D002273:Carcinogens; D018736:DNA Adducts; D009602:Nitrosamines; D011725:Pyridines; D006147:Guanine; C016583:4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone; C008449:O-(6)-methylguanine; D001189:Aryl Hydrocarbon Hydroxylases; C414206:CYP2A13 protein, human; C585520:Cyp2a5 protein, mouse; D065637:Cytochrome P-450 CYP2A6; D000072467:Cytochrome P450 Family 2; C099565:4-(methylnitrosamino)-1-(3-pyridyl)-1-butan-1-ol
references.citation: Drug Metab Dispos. 2012 Jun;40(6):1144-50
references.pmid: 22397853
references.citation: J Pharmacol Exp Ther. 2012 Apr;341(1):233-41
references.pmid: 22262919
references.citation: J Pharmacol Exp Ther. 2010 Feb;332(2):578-87
references.pmid: 19923441
references.citation: Chem Res Toxicol. 2005 Feb;18(2):95-110
references.pmid: 15720112
references.citation: Cancer Res. 2007 Aug 15;67(16):7825-32
references.pmid: 17699788
references.citation: IARC Monogr Eval Carcinog Risks Hum. 2007;89:1-592
references.pmid: 18335640
references.citation: Drug Metab Dispos. 2003 Oct;31(10):1199-202
references.pmid: 12975327
references.citation: Annu Rev Pharmacol Toxicol. 2003;43:149-73
references.pmid: 12171978
references.citation: Cancer Res. 1991 Oct 15;51(20):5557-64
references.pmid: 1913675
references.citation: J Pharmacol Exp Ther. 2007 Nov;323(2):570-8
references.pmid: 17671098
references.citation: Carcinogenesis. 1989 Oct;10(10):1901-4
references.pmid: 2791206
references.citation: Arch Biochem Biophys. 2000 Dec 15;384(2):418-24
references.pmid: 11368333
references.citation: Toxicol Sci. 2013 Oct;135(2):476-85
references.pmid: 23884085
references.citation: Cancer Res. 2000 Sep 15;60(18):5074-9
references.pmid: 11016631
references.citation: Cancer Res. 1993 Jun 15;53(12):2780-5
references.pmid: 8504419
references.citation: Cancer Lett. 2009 Mar 18;275(2):213-20
references.pmid: 19118942
references.citation: Cancer Res. 2003 Nov 15;63(22):8057-61
references.pmid: 14633739
references.citation: Chem Res Toxicol. 2003 Jun;16(6):794-806
references.pmid: 12807363
references.citation: Cancer Res. 1980 Feb;40(2):298-302
references.pmid: 7356512
references.citation: Drug Metab Dispos. 2008 Nov;36(11):2316-23
references.pmid: 18669584
references.citation: J Pharmacol Exp Ther. 2002 Aug;302(2):416-23
references.pmid: 12130698
references.citation: Xenobiotica. 2007 Dec;37(12):1439-49
references.pmid: 17922361
references.citation: Cancer Lett. 1998 Jul 17;129(2):131-8
references.pmid: 9719453
references.citation: Chem Res Toxicol. 1998 Jun;11(6):559-603
references.pmid: 9625726
references.citation: Cancer Res. 1992 Jun 1;52(11):3164-73
references.pmid: 1591728
references.citation: Carcinogenesis. 2005 Nov;26(11):1947-55
references.pmid: 15958517
references.citation: Cancer Res. 1992 Apr 1;52(7):1757-63
references.pmid: 1312898
references.citation: Cancer Lett. 1991 Jul 4;58(3):177-81
references.pmid: 1855194
references.citation: Cancer Res. 1993 Jul 15;53(14):3276-82
references.pmid: 8324738
references.citation: Carcinogenesis. 2011 Aug;32(8):1279-84
references.pmid: 21625009